Zhi Tong Cai Jing·2025-09-01 10:16Core Viewpoint - UBS reaffirms "Buy" rating for Tigermed (300347) with a target price increase from HKD 49.1 to HKD 56.3 [1] Financial Performance - Tigermed's Q2 revenue decreased by 0.7% year-on-year, a slight improvement from a 5.8% decline in Q1, with a quarter-on-quarter growth of 7.8% to RMB 1.69 billion, below market expectations of RMB 1.78 billion and UBS's estimate of RMB 1.85 billion [1] - Net profit fell by 15.5% year-on-year, improving from a 29.6% decline in Q1, totaling RMB 218 million, significantly lower than market forecasts of RMB 309 million and UBS's estimate of RMB 318 million, primarily due to revenue and margin declines [1] Forecast Adjustments - Due to underperformance in H1 2025, UBS has revised down its revenue and margin forecasts for Tigermed for 2025-2027, with earnings per share estimates reduced by 9.0%, 4.3%, and 0.1% respectively [1]